ArticleThe Kaohsiung journal of medical sciences2026
TET3-Mediated m5C Modification of CCAT2 Accelerates Cardiac Microvascular Endothelial Cell Damage in Acute Coronary Syndrome.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Acute coronary syndrome (ACS) is a clinical syndrome involving myocardial ischemia. This study aimed to elucidate the mechanism of TET3 in ACS-induced CMEC damage, thereby identifying a new target for ACS treatment. The expression of TET3 in ACS patients and healthy subjects was analyzed. CMECs were stimulated with ox-LDL and transfected with si-TET3 for the detection of TET3 RNA and protein levels. Cell proliferation, apoptosis, and angiogenesis were evaluated. Subsequently, m5C modification and TET3 enrichment on CCAT2 were assessed, and CCAT2 stability was measured. The binding relationships between CCAT2 and FUS and between FUS and TRIM14 mRNA were analyzed. Additionally, lncRNA CCAT2 inhibition or TRIM14 overexpression in combination with si-TET3 treatment was conducted to verify the underlying mechanism. TET3 was strongly expressed in serum from ACS patients and ox-LDL-stimulated CMECs, and silencing TET3 reduced ox-LDL-induced CMEC damage. TET3 removed m5C modification on CCAT2 to decrease CCAT2 stability and expression. With TRIM14, CCAT2 competes to bind to FUS to suppress TRIM14 expression. CCAT2 knockdown or TRIM14 overexpression partially reversed the protective effect of si-TET3 on CMEC damage. In conclusion, TET3 removed m5C modification to inhibit CCAT2 expression and reduced the binding relationship between CCAT2 and FUS to upregulate TRIM14, thereby exacerbating CMEC damage in ACS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.